Chadwick Boseman’s Death Highlights Need for Earlier Screening in Colorectal Cancer

Article

The recent death of Chadwick Boseman highlights the need for earlier screening in colorectal cancer, especially for young people.

Though the disease typically affects older adults, the recent death of Chadwick Boseman due to colorectal cancer (CRC) brought to light the fact that it is being found more often in younger adults, despite the traditional screening age, which is 50 years old, according to Dr. Mark Lewis of Intermountain Health.

In an interview with CURE®, Lewis, who is a cancer survivor himself, went on to explain that while the average age of his patients is around 68 years, there are an increasing number of cases of CRC being found in younger patients who wouldn’t fall into the typical screening age range. And in the case of Boseman’s death, Lewis concludes that Boseman’s death highlighted the disparities faced by not just by younger patients with CRC, but those in the Black community as well.

Transcription:

It just resonated so much with me because, you know, I think to lose a young and seemingly vibrant celebrity like that really brings to the forefront, something that we've seen now for a while, statistically, which is an upsurge in young-onset colorectal cancer, and as you pointed out before, the traditional age of screening, which is 50.

So, just to be clear about the demographics, this is still a disease that largely affects older adults. And we'll get into why that is, but it largely has to do with polyps and how long they're present and how long it takes for them to degenerate. So, the average age of my colorectal cancer patients in my practice, and I'm in the youngest state in the nation, which is Utah, the average age of those patients is 68. As you said, there's this increasingly substantial and worrisome minority for having a disease at a young age, and certainly an age before which they've traditionally been screened.

And so, Chadwick Boseman, unfortunately, I think has become sort of the face of this demographic, which disproportionately affects the African American community. So not only does he fit the demographic by age, he actually also fits it by ethnicity.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE